<DOC>
	<DOCNO>NCT00689767</DOCNO>
	<brief_summary>This First In Man study prospective , multicentre , single blind , randomize , control clinical trial CINATRA™ ISA 247 Coated Coronary Stent System compare CINATRA™ Coronary Stent System . The study enroll 100 evaluable patient 7 site . Clinical follow occur 1 month , 6 month , 1 , 2 , 3 , 4 5 year post procedure . Repeat angiography IVUS perform 6 month follow time point subject .</brief_summary>
	<brief_title>COronary Native Artery First Man Investigation ISA 247 Elution Prevent Restenotic Mechanisms ( CONFIRM 1 )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Patients stable angina pectoris ( Canadian Cardiovascular Society 1 , 2 , 3 ) unstable angina pectoris document ischemia ( CCS 4 , Braunwald Class IBC , IIBC IIIBC ) , patient document silent ischemia . 2 . Patients eligible coronary revascularization ( percutanous angioplasty ) . 3 . Acceptable candidate coronary artery bypass grafting ( CABG ) . 4 . Patients de novo lesion native coronary artery &gt; 50 % &lt; 100 % stenosis . NOTE : Treatment lesion nontarget vessel investigator 's discretion ( max . twovesseldisease ) . ONLY bare metal stent ( drug elute stent ) use treatment . Treatment nontarget vessel lesion must successfully complete enrol patient place study stent . 5 . The target lesion must maximum length 13 mm ( visual estimate ) able cover one stent . 6 . The reference diameter target lesion must 3.0 mm visual estimate . 7 . Left ventricular ejection fraction &gt; 30 % . 8 . Patients willing provide write informed consent prior participation willing able participate followup evaluation . 1 . Patients age 18 unable give inform consent . 2 . Women pregnant . Women child bear potential must negative pregnancy test within 7 day prior enrollment utilize reliable contraception minimum angiographic follow . 3 . Patients previously participate study . 4 . Patient currently participate investigational drug device study complete primary endpoint clinically interfere current study endpoint . NOTE : Trials require extend followup product investigational , since become commercially available , consider investigational trial . 5 . Life expectancy le 12 month factor make clinical and/or angiographic followup difficult ( fixed address , etc. ) . 6 . Patients intend major surgical intervention within 6 month enrollment study . 7 . Patients new ST elevation within 48 hour prior stenting . 8 . Braunwald Class IA , IIA IIIA angina pectoris . 9 . Patients contraindication emergency coronary bypass surgery . 10 . Patients previous Coronary Artery Bypass Surgery ( CABG ) . 11 . Any individual may refuse blood transfusion . 12 . Serum creatinine &gt; 3.0 mg/dL . 13 . Platelet count &lt; 100,000 cells/mm³ . 14 . Patients intolerance contraindication acetylsalicylic acid ( aspirin ) , heparin , cyclosporin cyclosporine derivative , clopidogrel ticlopidine drug therapy . 15 . Patients contrast agent hypersensitivity adequately premedicated . 16 . Patients stent anywhere within target vessel . 17 . Any planned interventional treatment vessel post study procedure . Exclusion Criteria Related Angiography 18 . Patients previous PCI segment ( i.e . restenotic lesion ) . 19 . Previous interventional procedure ( le 6 month ) anywhere within target vessel ; 20 . Target lesion locate supply arterial venous bypass graft . 21 . Target lesion involves side branch &gt; 2.0mm diameter . 22 . Ostial target lesion ( within 3.0mm vessel origin ) . 23 . Target vessel evidence thrombus excessively tortuous make unsuitable proper stent delivery deployment . 24 . Patients total occlusion ( TIMI 0 ) . 25 . Significant ( &gt; 50 % ) stenosis proximal distal target lesion might require revascularization impede run . 26 . Target lesion require treatment device predilatation balloon prior stent placement ( include limit , directional coronary atherectomy , excimer laser , rotational atherectomy , cut balloon etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>drug elute stent</keyword>
</DOC>